Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients

Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients

Background: Many studies have evaluated the use of hydroxychloroquine in COVID-19. Most retrospective observational studies demonstrate a benefit of using HCQ on mortality, but not most randomized clinical trials. Methods: We analyzed raw data collected from a cohort of 30,423 patients with COVID-19...

Full description

Bibliographic Details
Main Authors: Philippe Brouqui, Matthieu Million, Philippe Parola, Peter A. Mccullough, Didier Raoult
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:New Microbes and New Infections
Subjects:
SARS-CoV-2
COVID-19
Hydroxychloroquine
Azithromycin
Survival
Mortality
Online Access:http://www.sciencedirect.com/science/article/pii/S2052297523001075

Internet

http://www.sciencedirect.com/science/article/pii/S2052297523001075

Similar Items